Andreas Charidimou1, Gregoire Boulouis2, Sara Shams3, David Calvet4, Ashkan Shoamanesh5. 1. Department of Neurology, Massachusetts General Hospital Stroke Research Center, Harvard Medical School, Boston, MA, USA. Electronic address: andreas.charidimou.09@ucl.ac.uk. 2. Université Paris-Descartes, INSERM U894, CH Sainte-Anne, Department of Neuroradiology, Paris, France. 3. Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden. 4. Department of Neurology, Centre Hospitalier Sainte-Anne, Université Paris Descartes, DHU Neurovasc Sorbonne Paris Cité, INSERM U894, Paris, France. 5. Department of Medicine (Neurology), McMaster University, Population Health Research Institute, Hamilton, Ontario, L8L 2X2, Canada.
Abstract
INTRODUCTION: Whether ischaemic stroke patients with atrial fibrillation (AF) and cerebral microbleeds (CMBs) on MRI can be safely anticoagulated is a hotly debated topic. We performed a systematic review and meta-analysis of published aggregate data, to investigate the risk of subsequent intracerebral haemorrhage (ICH) based on CMBs presence in this stroke population, generally considered for oral anticoagulation. We also suggest a decision-making schema for anticoagulation use in this setting. METHODS: We searched PubMed for relevant observational studies. Random effects models with DerSimonian-Laird weights were used to investigated the association between CMBs presence at baseline MRI and ICH or ischaemic stroke during follow-up. RESULTS: Four studies, with slightly heterogeneous design, including 990 ischaemic stroke patients were pooled in a meta-analysis (crude CMBs prevalence: 25%; 95%CI: 17%-33%). The median follow-up ranged between 17 and 37months. The future symptomatic ICH rate was 1.6% (16/990), while recurrent ischaemic stroke rate was 5.9% (58/990). Baseline CMB presence was associated with increased risk of symptomatic ICH during follow-up compared to patients without CMBs (OR: 4.16; 95%CI: 1.54-11.25; p=0.005). There was no association between CMBs presence and recurrent ischaemic stroke risk. CONCLUSION: We have shown that the presence of CMBs in cohorts of ischaemic stroke patients, most with AF on warfarin, is associated with a 4-fold increase in subsequent ICH (but not ischaemic stroke) risk (Class III evidence). These pooled estimates are useful for future trials design. We propose a simple data-driven anticoagulation schema which awaits validation and refinement as new prospective data are accumulated.
INTRODUCTION: Whether ischaemic strokepatients with atrial fibrillation (AF) and cerebral microbleeds (CMBs) on MRI can be safely anticoagulated is a hotly debated topic. We performed a systematic review and meta-analysis of published aggregate data, to investigate the risk of subsequent intracerebral haemorrhage (ICH) based on CMBs presence in this stroke population, generally considered for oral anticoagulation. We also suggest a decision-making schema for anticoagulation use in this setting. METHODS: We searched PubMed for relevant observational studies. Random effects models with DerSimonian-Laird weights were used to investigated the association between CMBs presence at baseline MRI and ICH or ischaemic stroke during follow-up. RESULTS: Four studies, with slightly heterogeneous design, including 990 ischaemic strokepatients were pooled in a meta-analysis (crude CMBs prevalence: 25%; 95%CI: 17%-33%). The median follow-up ranged between 17 and 37months. The future symptomatic ICH rate was 1.6% (16/990), while recurrent ischaemic stroke rate was 5.9% (58/990). Baseline CMB presence was associated with increased risk of symptomatic ICH during follow-up compared to patients without CMBs (OR: 4.16; 95%CI: 1.54-11.25; p=0.005). There was no association between CMBs presence and recurrent ischaemic stroke risk. CONCLUSION: We have shown that the presence of CMBs in cohorts of ischaemic strokepatients, most with AF on warfarin, is associated with a 4-fold increase in subsequent ICH (but not ischaemic stroke) risk (Class III evidence). These pooled estimates are useful for future trials design. We propose a simple data-driven anticoagulation schema which awaits validation and refinement as new prospective data are accumulated.
Authors: Juliane Herm; Johannes Schurig; Martin R Martinek; Reinhard Höltgen; Alexander Schirdewan; Paulus Kirchhof; Marcus Wieczorek; Helmut Pürerfellner; Peter U Heuschmann; Jochen B Fiebach; Karl Georg Haeusler Journal: BMC Cardiovasc Disord Date: 2019-03-12 Impact factor: 2.298
Authors: Lisa Hert; Alexandros A Polymeris; Sabine Schaedelin; Johanna Lieb; David J Seiffge; Christopher Traenka; Joachim Fladt; Sebastian Thilemann; Henrik Gensicke; Gian Marco De Marchis; Leo Bonati; Philippe Lyrer; Stefan T Engelter; Nils Peters Journal: Eur Stroke J Date: 2019-11-12
Authors: Kara R Melmed; Meng Cao; Siddhant Dogra; Ruina Zhang; Shadi Yaghi; Ariane Lewis; Rajan Jain; Seda Bilaloglu; Ji Chen; Barry M Czeisler; Eytan Raz; Aaron Lord; Jeffrey S Berger; Jennifer A Frontera Journal: J Thromb Thrombolysis Date: 2020-09-24 Impact factor: 2.300